212 related articles for article (PubMed ID: 17854248)
21. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
22. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
23. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
Ahlskog JE
Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
[TBL] [Abstract][Full Text] [Related]
24. Non-ergot dopamine agonist-induced sleep attacks.
Ryan M; Slevin JT; Wells A
Pharmacotherapy; 2000 Jun; 20(6):724-6. PubMed ID: 10853628
[TBL] [Abstract][Full Text] [Related]
25. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
26. Could pramipexole induce acute mania? A case report.
Bet PM; Franken LG; Klumpers UM
Bipolar Disord; 2013 Jun; 15(4):446-8. PubMed ID: 23581392
[TBL] [Abstract][Full Text] [Related]
27. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
28. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction.
Burdick KE; Braga RJ; Nnadi CU; Shaya Y; Stearns WH; Malhotra AK
J Clin Psychiatry; 2012 Jan; 73(1):103-12. PubMed ID: 22152405
[TBL] [Abstract][Full Text] [Related]
29. Dopaminergic agonists in Parkinson's disease.
Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
[TBL] [Abstract][Full Text] [Related]
30. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
32. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for the development of pedal edema in patients using pramipexole.
Kleiner-Fisman G; Fisman DN
Arch Neurol; 2007 Jun; 64(6):820-4. PubMed ID: 17420306
[TBL] [Abstract][Full Text] [Related]
34. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
35. Role of pramipexole in the management of Parkinson's disease.
Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
[TBL] [Abstract][Full Text] [Related]
36. Neuropsychological findings in a case of punding before and after cessation of pramipexole.
Larson ER
Clin Neuropsychol; 2015; 29(1):166-78. PubMed ID: 25658417
[TBL] [Abstract][Full Text] [Related]
37. Pramipexole-induced psychosis in Parkinson's disease.
Li CT; Tsai SJ; Hwang JP
Psychiatry Clin Neurosci; 2008 Apr; 62(2):245. PubMed ID: 18412854
[No Abstract] [Full Text] [Related]
38. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Micallef J; Rey M; Eusebio A; Audebert C; Rouby F; Jouve E; Tardieu S; Blin O
Br J Clin Pharmacol; 2009 Mar; 67(3):333-40. PubMed ID: 19220275
[TBL] [Abstract][Full Text] [Related]
39. Pramipexole for depression.
Ostow M
Am J Psychiatry; 2002 Feb; 159(2):320-1. PubMed ID: 11823287
[No Abstract] [Full Text] [Related]
40. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
